Compare Domino's Pizza, Inc. (DPZ) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Domino's Pizza, Inc. vs Davita Inc — how do they compare? Domino's Pizza, Inc. trades at $308.02 (market cap $10.03B), while Davita Inc trades at $175.04 (market cap $11.28B). The key difference: Domino's Pizza, Inc. and Davita Inc are close in size by market cap, and Domino's Pizza, Inc. pays a 2.63% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Domino's Pizza, Inc. for 106 Days and Davita Inc for 113 Days on average.
| DPZ | DVA | |
|---|---|---|
Market Cap | $10.03B | $11.28B |
Volume | 892,489 | 650,294 |
Sector | Consumer Cyclical | Health |
52-Week High | $438.42 | $240.96 |
52-Week Low | $282.89 | $103.87 |
Typical Hold Time | 106 Days | 113 Days |
Enterprise Value | $14.99B | $24.00B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Domino's Pizza (DPZ) trades at $308.65, up 1.91% today, with a bullish technical signal despite recent earnings misses. Revenue has grown steadily to $4.94B in 2025, with a net margin of 11.86%, though the stock faces headwinds from high debt levels and flat dividend growth. Analyst consensus is a Buy with a $373 price target, but news highlights store closures and competitive pressures.
The outlook is mixed: strong cash flow and brand strength support upside, but debt burden and margin pressure pose risks. Investors should weigh analyst optimism against execution challenges in a competitive sector.
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Read more on DPZ →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
